Pneumotox » Drug » Cytosine arabinoside - Aracytine - Cytarabine - Ara-C

Cytosine arabinoside - Aracytine - Cytarabine - Ara-C

3

Last update : 20/09/2014

I.a Pneumonitis (ILD), acute and/or severe (may cause ARDS)

1

I.d Organizing pneumonia pattern (an area or areas of consolidation on imaging)

1

I.k Lung nodule or nodules

1

I.l Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf)

2

II.a Pulmonary edema, noncardiogenic (NCPE)

3

II.b ARDS - Acute lung injury

2

III.a Alveolar hemorrhage (AH), diffuse AH (DAH)

1

V.i Pleuritis (can cause chest pain)

1

V.m Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative)

1

X.c Capillary leak syndrome (CLS)

2

X.o Neutrophilic dermatosis (Pyoderma, Sweet syndrome)

1

XII.c Pericardial effusion (w/wo tamponade)

1

XII.e Takotsubo (stress) cardiomyopathy

1

XV.f Path: Diffuse alveolar damage (DAD-pattern) (see also IL)

1

XVI.v Imaging: Centrilobular micronodules (can be diffuse)

1

XVII.e Pneumocystis jiroveci pneumonia

1

XXIV.a Veterinary: Pneumonitis - Interstitial lung disease

1

Diagnosing DIRD

1

Drug and radiation history

2

Drug singularity - Correct identification of the drug

3

Consistent timing of exposure v. onset of symptoms

4

Clinical, imaging, BAL, pathological pattern consistent with the specific drug

5

Careful exlusion of another cause

6

Remission of symptoms with removal of drug

7

Recurrence with rechallenge (rarely advisable)

8

Causality assessment

More detailed checklist